focus -WSS

focus

author：fashion 2025-09-27 16:46:41 - browse：23

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： New menopause drug shows promise in relief for hot flashes

WSS

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Idaho abortion case may prompt more restrictions in other states

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Heart disease and mental health: A look at cardiac psychology

Printout prescription drug information shouldn’t go digital

Idaho abortion case may prompt more restrictions in other states

focus

focus

focus

Cancer drug shortages should be causing more outrage

Doulas covered by Medicaid under New York's new plan

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Printout prescription drug information shouldn’t go digital

New air purifier tech could be key to improving indoor air quality

To bolster infectious disease surveillance, genomics powerhouses team up

The cancer drug shortage isn’t new — and neither are the solutions

DeSantis can now import cheaper drugs. But will Biden get credit?

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Future doctors need a strong humanities education

leisure time

HHS names first

TikTok, Instagram influencers need more rules for drug ads

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

New Medicare drug pricing powers could soon be upended in court

FDA sets aggressive timeline for overhauling inspection procedures

Microsoft launches AI tool for clinical documentation through Epic

leisure time

entertainment

leisure time

focus